Marketing ended · 30.10.2026
Supply shortage Belgium: Azacitidin Sandoz 25 mg/ml inj. susp. (pwdr.) s.c. vial 100 mg – Marketing ended, 30.10.2026 · ENR BE563022
Affected country: Belgium · Reported period: 01.04.2027 – not specified · Active ingredient: Azacitidine
Active ingredients
Notice context
A supply shortage has been recorded for Azacitidin Sandoz 25 mg/ml inj. susp. (pwdr.) s.c. vial 100 mg in Belgium. The stated reason is “Commercial reasons”. The notice concerns the active ingredient Azacitidine and is not identified as hospital-relevant.
This information describes the reported supply status and is not medical or pharmaceutical treatment advice. Availability, alternatives and further measures must be assessed for each individual case by the responsible pharmaceutical market participants.
Official shortage notice for Belgium. Responsibility and update procedures follow the information supplied by the relevant authority.
Check the official notice list →Implications for procurement and the supply chain
The notice for Azacitidin Sandoz 25 mg/ml inj. susp. (pwdr.) s.c. vial 100 mg is a supply signal concerning Azacitidine in Belgium. The published reason “Commercial reasons” determines which data should be verified first.
Because the published reason does not establish a reliable operational cause, availability, source, timing, product status and the supply route should be verified without adding an unsupported explanation.
Once a lawful sourcing route is confirmed and buffer stock is required, our pharma warehouse in Cheb page explains receipt, stock control and picking.
Decision route for this supply case
- Confirm the notice, product identity, period and actual demand with the primary source and accountable market participants.
- Assess source, product status, timing, lawful sourcing route and any buffer stock without adding an unsupported cause.
- Document release, stock status, GDP evidence, warehousing and transport process, and escalation responsibility.
Inter-Pharma can structure the B2B case, potential sourcing and warehousing routes, and operational implementation. Clinical decisions, regulatory permissibility, product release and actual availability remain with the accountable parties.
Request a structured supply review →Operational shortage resilience: GDP warehousing and pharmaceutical storage
A resilient stock concept for Azacitidin Sandoz 25 mg/ml inj. susp. (pwdr.) s.c. vial 100 mg requires prior verification of product status, demand, coverage and the permitted supply route.
Inter-Pharma combines GDP-oriented pharmaceutical storage in Czechia with batch and expiry control, FEFO, stock status, picking and dispatch preparation in its own Cheb operation.
Storage at 15–25 °C or any 2–8 °C requirement is derived solely from the product specification and confirmed for the project.
Operational checks for this notice
- Match product identity using CNK 4245809, active ingredient, strength, dosage form and pack.
- Confirm the reported status and the period 01.04.2027 to nicht angegeben with the primary source and potential suppliers.
- Document demand, stock coverage, open orders and lawful alternative or sourcing routes for the specific case.
- Clarify temperature, batch, expiry, stock status, recipient authorisation and GDP evidence before cross-border supply.
Relevant services and specialist pages
The following B2B topics are particularly relevant when handling a shortage involving Azacitidin Sandoz 25 mg/ml inj. susp. (pwdr.) s.c. vial 100 mg: